L‐ornithine L‐aspartate vs lactulose
Serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes serious adverse events assessed using ICH‐GCP compared with lactulose (very low certainty).
1 finding from 1 review
- L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2018 · Cochrane Headline outcomes onlyRR 0.69 [0.22, 2.11]3 studies · 144 participantsVery low